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Abstract Cardiovascular diseases are the leading cause of
death not only in Europe but also in the rest of the World.
Preventive measures, however, often fail and cardiovascular
disease may manifest as an acute coronary syndrome, stroke
or even sudden death after years of silent progression. Thus,
there is a considerable need for innovative diagnostic and
therapeutic approaches to improve the quality of care and
limit the burden of cardiovascular diseases. During the past
10 years, several retrospective and prospective clinical studies
have been published using 18F-fluorodeoxyglucose (FDG)
positron emission tomography (PET) to quantify
inflammation in atherosclerotic plaques. However, the current
variety of imaging protocols used for vascular (arterial) im-
aging with FDG PET considerably limits the ability to com-
pare results between studies and to build large multicentre
imaging registries. Based on the existing literature and the
experience of the Members of the European Association of
Nuclear Medicine (EANM) Cardiovascular Committee, the
objective of this position paper was to propose optimized
and standardized protocols for imaging and interpretation of
PET scans in atherosclerosis. These recommendations do not,
however, replace the individual responsibility of healthcare
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professionals to make appropriate decisions in the circum-
stances of the individual study protocols used and the indi-
vidual patient, in consultation with the patient and, where
appropriate and necessary, the patient’s guardian or carer.
These recommendations suffer from the absence of conclu-
sive evidence on many of the recommendations. Therefore,
they are not intended and should not be used as "strict guide-
lines" but should, as already mentioned, provide a basis for
standardized clinical atherosclerosis PET imaging protocols,
which are subject to further and continuing evaluation and
improvement. However, this EANM position paper might
indeed be a first step towards "official" guidelines on athero-
sclerosis imaging with PET.
Keywords Atherosclerosis . Positron emission tomography .
Position paper
Background
Cardiovascular diseases (CVD) are the leading cause of
death in Europe (5 million deaths per year) and in the
world (19 million deaths per year) irrespective of low-
or middle-income countries [1, 2]. More than one in
three adults in Western countries die from coronary ar-
tery disease and about 25 % from stroke. The cost of
CVD in the European Union was €196 billion in 2009.
There has been considerable progress in prevention and
treatment of CVD. Prevention of CVD has largely been
achieved through treatment of risk factors (in particular
treatment of dyslipidaemia with statins), and develop-
ment of potent anticoagulant and antiplatelet therapies.
Improved treatment of CVD has been possible through
the widespread availability of balloon angioplasty and
stent implantation as well as cardiac surgical procedures
for the local treatment of occluded or highly stenotic
arteries. Preventive measures, however, often fail and
CVD may manifest as an acute coronary syndrome,
stroke or even sudden death after years of silent pro-
gression [3].
Thus, there is a considerable need for innovative diagnostic
and therapeutic approaches to improve the quality of care and
limit the burden of CVD.
Atherosclerosis is responsible for the vast majority of
heart attacks, strokes and peripheral vascular disease. It
is characterized by accumulation of lipids, inflammatory
cells and connective tissue within the arterial wall lead-
ing to the formation of atherosclerotic plaques [4–6].
Atherosclerotic changes in the vessel wall reflect a
chronic, progressive disease, which has a long asymp-
tomatic phase, and atherosclerotic plaques can remain
quiescent for years but can become life threatening
when they rupture. Rupture of such a plaque (a so-
called vulnerable plaque) initiates clot formation in the
vessel lumen which disturbs blood flow and from which
emboli may break off and lodge in the downstream
circulation. Plaque rupture can lead ultimately to acute
myocardial infarction or stroke. Unfortunately, no eval-
uated biomarker or imaging technique is available that
can predict the risk in a particular patient of plaque
rupture and a subsequent acute cardiovascular event.
Whether and how a plaque ruptures is determined by
its macroscopic structure and its microscopic composi-
tion [7]. Arterial wall inflammation seems to play a key
role in atherosclerotic plaque rupture leading to clinical
cardiovascular events. Therefore, detection of arterial
inflammation with imaging is an attractive approach to
identifying patients at highest risk of plaque rupture
[8].
18F-fluorodeoxyglucose (FDG) is a glucose analogue
that is taken up by cells with high metabolic activity
such as inflammatory and tumour cells. Its uptake in
tissues can be quantified by positron emission tomogra-
phy (PET) imaging. Accumulation of FDG in the arte-
rial wall is thought to reflect increased inflammation in
atherosclerotic plaques [9, 10]. During the past 10 years,
several retrospective and prospective clinical studies
have used FDG PET imaging for the quantification of
the intensity of inflammation in atherosclerotic plaques.
Signal quantification in the vessel wall measured with
FDG PET is, however, strongly influenced by the pa-
rameters selected for PET image acquisition including
delay between FDG injection and imaging, the approach
used for signal quantification and the use of correction
factors. The current variety of imaging protocols used
for vascular (arterial) imaging with FDG PET consider-
ably limits the ability to compare results between stud-
ies and to build large multicentre imaging registries.
The objective of this position paper was to review the
different parameters that might influence FDG uptake in
atherosclerotic plaques, and propose optimized standard-
ized scan protocols for imaging atherosclerosis with
PET based on the existing literature and the experience
of the members of the EANM Cardiovascular
Committee. We limited this position paper to the imag-
ing of atherosclerosis in relatively larger arterial vessels.
Imaging of the coronary arteries is only briefly men-
tioned and is not discussed in full here. With this posi-
tion paper, we hope to standardize the practice of arte-
rial PET imaging in European nuclear medicine centres
and thereby facilitate (multicentre) clinical studies on
the imaging of atherosclerosis with PET. In addition this
harmonization of protocols would ultimately allow better
extrapolation of acquired data and therefore optimized
applicability of this imaging modality in the setting of
atherosclerosis.
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Technical recommendations for imaging
atherosclerosis with FDG PET
FDG: dose, timing after injection (circulation time),
prescan fasting glucose
Injected dose of FDG
The dose of FDG administered in clinical studies varies con-
siderably ranging from 185 MBq to 925 MBq [10–12].
Factors to take into consideration to define the dose of FDG
injected are the sensitivity of the PET scanner (in particular,
2D vs. 3D acquisitions), the duration of imaging steps, the
body weight of the patient, and the delay between tracer in-
jection and image acquisition. As for other clinical indica-
tions, the ALARA (As Low As Reasonably Achievable) prin-
ciple should apply to vascular imaging studies. The exposure
of patients to radiation should be kept as low as possible, in
particular in studies monitoring changes of FDG uptake in
atherosclerotic plaques over time or the effects of treatments
requiring repeated FDG PET imaging studies. Only one study
has directly evaluated the impact of the injected FDG dose in
vascular FDG PET imaging in atherosclerosis [13]. In this
study, the injection of a lower dose of FDG had neither an
impact on the quantification of FDG uptake (standardized
uptake value, SUV, and target to background ratio, TBR),
nor an impact on the classification of patients into tertiles
based on the intensity of FDG uptake [13].
Section summary and recommendations:
& Considering a circulation time of 2 h for vascular imaging
(see below), we recommend that the injected activity of
FDG should be between 3 and 4 MBq/kg body weight for
atherosclerotic plaque imaging to allow sufficient image
quality. In patient screening and/or repeated PET studies,
lower FDG activities need to be considered to limit the
patient's total radiation exposure. Further studies are re-
quired to evaluate whether lower FDG activities leading
to lower exposure of patients to radiation still provide
appropriate image quality.
Delay between FDG injection and PET acquisitions (FDG
circulation time)
For arterial imaging with PET, longer delays between FDG
injection and PET imaging than those used for oncology are
recommended to allow sufficient FDG accumulation in the
arterial wall and to reduce the intensity of FDG signal in the
blood. The FDG circulation time is critical as optimal contrast
between the target (plaque, arterial wall) and the background
(blood) is essential to ensure accurate quantification of plaque
FDG uptake [9, 11, 13–19]. Improved target-to-background
contrast is typically achieved by delayed imaging [13, 20]. In
addition, vascular imaging with PET is subject to partial vol-
ume effects (PVE). The intensity of the signal measured in the
arterial wall with FDG PET imaging is strongly influenced by
the adjacent background signal from circulating blood.
Therefore, the blood signal should be kept as low as possible
for precise quantification of FDG uptake in atherosclerotic
plaques.
Dynamic PETstudies have been performed both in patients
with carotid artery disease and in animal models of atheroscle-
rosis [9, 11, 13, 14, 21]. At earlier time-points (1 h), the con-
trast between FDG uptake in the vessel wall and the residual
blood signal is suboptimal leading to underestimation of FDG
uptake in the vessel wall, whereas at later time-points
(2.5 – 3 h) FDG uptake measured with PET approaches the
true vascular FDG uptake [9]. Delays between FDG injection
and imaging of >3 h do not provide any additional improve-
ment in the quantification of FDG uptake in the vessel wall.
Tawakol et al. using a delay between FDG injection and PET
acquisition of 3 h found excellent correlations between the
intensity of FDG uptake measured in carotid atherosclerotic
plaques and the density of macrophages measured on corre-
sponding histological sections obtained after carotid endarter-
ectomy [9].
Section summary and recommendations:
& Based on these results, we recommend the acquisition of
PET images 2 h after injection for reliable quantification
of FDG uptake in the arterial vessel wall and/or plaques. In
our opinion, this imaging delay represents the best com-
promise between a low background signal in blood and an
acceptable duration of the PET study for patients.
Prescan fasting glucose
In oncological studies, the intensity of FDG uptake in tumour
tissues is influenced by the patient's prescan glucose levels
[22–24]. The observed reduction in FDG uptake is most likely
due to competition between glucose and FDG as facilitative
transport via the glucose transporter protein (GLUT) system is
the most important way by which both glucose and FDG enter
human cells [25]. Additionally, the intensity of FDG uptake in
macrophages in cell culture depends not only on the duration
of culture and the degree of macrophage activation but also on
the prevailing glucose concentration, such that FDG uptake
decreases with increasing glucose concentration in the culture
medium [25]. As diabetes is a major risk factor for atheroscle-
rotic disease, the problem of elevated prescan glucose levels
occurs frequently in patients scheduled for FDG PET imaging
of vessel wall inflammation.
The impact of glucose levels on FDG uptake in inflamma-
tory lesions has been less studied than in tumour cells. Cell
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culture experiments suggest that moderate hyperglycaemia
(up to 250 mg/dl, 14 mmol/l) does not adversely affect FDG
uptake in inflammatory cells [23, 26]. In contrast, data from
experimental studies in rats show a significant reduction in
FDG uptake in the lesions of infectious and noninfectious
inflammatory models with moderate hyperglycaemia
(150 – 180 mg/dl, 8.3 – 10.0 mmol/l) but also, after glucose
loading, decreased GLUT-1 and GLUT-3 expression in infec-
tious lesions [27, 28].
In a prospective study by Bucerius et al. [13], a negative
correlation was found between prescan glucose levels and
SUV and TBR values measured in the ascending aorta and
the carotid arteries. Elevated prescan glucose values were as-
sociated with increased FDG blood pool activity [13]. As
blood pool activity is used as the denominator in calculating
TBR, this might explain at least in part the lower TBR values
measured in patients with high prescan glucose values.
Furthermore, prescan glucose levels higher than 126 mg/dl
(7.0 mmol/l) have been found to be associated with lower
TBR values, whereas prescan glucose values below this level
did not show any effect on TBR values [13].
In a patient with a blood glucose level above 126 mg/dl
(7.0 mmol/l) approaches to lower the patient's glucose level
could be considered [29]. Such approaches include adminis-
tration of rapid-acting insulin with an appropriate time of 4 h
between administration of insulin and injection of FDG or
asking the patient to hydrate while ambulating and recheck
the blood glucose level periodically until an acceptable level
has been achieved. However, all of these approaches relate to
oncological FDG PET imaging and are included in the EANM
recommendations for oncological PET imaging, and data re-
garding their performance in atherosclerosis imaging with
FDG PET are still lacking [29]. This also holds true for the
preparation of patients with type II diabetes mellitus in whom
an appropriate preparation before the scan is even more cru-
cial, particularly if intravenous administration of contrast agent
is necessary. In these circumstances, if the patient is taking
metformin, this medication should be discontinued at the time
of the procedure and withheld for 48 h after the procedure
under the appropriate control of the referring physician [29].
As mentioned above, due to a lack of data regarding the opti-
mal protocols for reducing high glucose levels in patients
scheduled for atherosclerotic FDG PET imaging, we refer to
the EANM recommendations for oncological patients [29].
However, until sufficient data are available to provide specific
recommendations for glucose adjustment in vascular patients,
these recommendations should be applied somewhat cautious-
ly in patients undergoing atherosclerotic FDG PET imaging.
In patients in whom blood glucose levels below approxi-
mately 130 mg/dl (approximately 7.0 – 7.2 mmol/l) cannot be
achieved using the approaches mentioned above, a correction
of the vascular FDG uptake according to the EANM recom-
mendations for oncological PET imaging can be considered
[29]. This approach was applied on a previous study on ath-
erosclerotic PET imaging using a dedicated formula normal-
izing the measured glucose content for an overall population
average of 90 mg/dl (5.0 mmol/l): SUVgluc=SUV×patient's
blood glucose in milligrams per decilitre (mmol/l)/90 mg/dl
(5.0 mmol/l) [30].
Section summary and recommendations:
& Taken together, these studies suggest that arterial imaging
should ideally be performed in patients with prescan glu-
cose levels lower than approximately 130 mg/dl (approx-
imately 7.0 – 7.2 mmol/l). In patients in whom these blood
glucose levels cannot be achieved by other approaches as
described above, correction of the vascular FDG uptake
according to the EANM recommendations for oncological
PET imaging can be considered. However, this needs to be
validated more extensively in the setting of vascular wall
imaging with FDG PET.
PET reconstruction protocols for vascular imaging
in atherosclerosis
Accurate estimation of radiotracer uptake in arterial lesions is
extremely challenging given the small size of the lesions com-
pared to the spatial resolution of PET. In particular, uptake
measurements in the arterial walls are strongly affected by
PVE, which cause large activity underestimation in structures
that are typically less than three times the spatial resolution in
the reconstructed images [31]. Assuming a constant uptake in
a lesion, the bias in uptake measurements introduced by PVE
depends on a number of factors, including the volume of the
lesion, its shape and contrast with respect to surrounding tis-
sue, the spatial resolution in the PET images and motion arte-
facts. It also depends on how the uptake is measured [32, 33].
The smaller the lesion, the greater the underestimation of ac-
tivity in that lesion, since activity within the lesion spills out of
the lesion due to the blurring caused by the point spread func-
tion (PSF) in the reconstruction algorithm of the PET imaging
system. In addition, when lesion activity is very different from
that of surrounding tissues (high contrast), the spill out is not
compensated for by the spill-in of activity located outside the
lesion. Conversely, when the lesion is large, PVE is not so
severe [31]. Using simulated lesions, Huet et al. found that
the true SUV in atherosclerotic plaques is largely
underestimated, up to a factor of 7 whatever the PET acquisi-
tion and reconstruction protocol [34]. This is particularly true
when compared to the spatial resolution of the reconstructed
images (around 5 mm), since the FDG signal is located in a
relatively small area (<1 mm) within the atherosclerotic
lesion.
Despite the strong underestimation of the FDG signal in
atherosclerotic lesions, several PET acquisition parameters
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can be optimized for arterial imaging to limit this bias.
Overall, for a standard deviation in the measurement of less
than 0.5 SUVunits, the lowest bias was always found using an
8-min PET acquisition and reconstruction including a PSF
model using a voxel size of 1×1×1 mm and no postfiltering,
with at least 120 iterations when using an OSEM approach
(Table 1). If these acquisition parameters are used the devia-
tion in SUV is less dependent on the dimension of the athero-
sclerotic lesion [33, 34].
However, even with these optimized parameters, the mean
error in SUV remained high because of PVE. Several strate-
gies might be considered in the future to reduce these errors:
improving the spatial resolution of the PET images based on
hardware development and implementing explicit partial vol-
ume correction and motion correction, especially in coronary
arteries [33, 35].
Section summary and recommendations:
& Reconstruction parameters for PET images may influence
SUV and TBR quantification. We therefore recommend
the implementation of dedicated PETacquisition, process-
ing and reconstruction protocols for arterial imaging as
described above and in Table 1.
Parameters for quantification of radiotracer uptake
in atherosclerotic plaques
Accurate quantification of radiotracer activity in arterial wall
or plaque on PET images can be problematic. SUV (i.e. the
decay-corrected tissue concentration in in kilobecquerels per
millilitre divided by the injected dose per body weight in
kilobecquerels per gram) is the most commonly used param-
eter for measuring lesion activity in patients undergoing PET/
CT imaging for the initial diagnosis, staging or evaluation of
treatment response of malignancies. Maximal SUV (SUVmax)
is the most intense voxel activity within a region of interest
(ROI) while mean SUV (SUVmean) is the mean SUV within
the ROI. On the one hand, SUVmean is not a realistic measure
in atherosclerotic plaque quantification because it is almost
impossible to accurately define the edge of an arterial plaque
on CT images. On the other hand, SUVmax may not accurately
represent the lesion’s overall activity as tracer distribution is
often not homogeneous within a lesion. SUVmax is, however,
the most commonly used parameter to quantify FDG uptake in
atherosclerotic plaques. SUVmax measurements in plaques re-
flect the part of the lesion with the highest FDG uptake. The
level of noise in the image and the adjacent blood signal (spill-
in of adjacent activity related to PVE) can influence measure-
ments of SUVmax.
As discussed above, quantification of FDG uptake in vas-
cular imaging using SUVmax is improved by the use of late
time-points and long acquisition times. SUVmax values
measured in atherosclerotic plaques tend to underestimate
the true FDG uptake by a factor up to 7 depending on the size
of the lesion as compared to the spatial resolution of the sys-
tem. In addition, overcorrection of heavily calcified arteries by
low-dose CT might also lead to an underestimation of the true
FDG uptake. Development of algorithms for correction of
PVE in arterial lesions in association with improved identifi-
cation of plaque contours based on high-resolution, high-
contrast MR images, which are now becoming available with
combined PET/MRI systems, might help to quantify more
precisely the intensity of radiotracer uptake in atherosclerotic
plaques [36].
An unique parameter that is used only in vascular imaging
is the TBR, which was used for the first time in arterial FDG
PET imaging in 2006, and which has since been widely used
in several studies [9]. The TBRmax is calculated as the ratio of
SUVmax measured in atherosclerotic plaques or the arterial
vessel wall and venous blood pool mean SUVmean to correct
for blood-pool uptake. TBR measured in atherosclerotic
plaques on FDG PET/CT has been shown to correlate well
with plaque macrophage density on corresponding histologi-
cal sections [9, 10, 37–39]. In addition, TBR values measured
in different arterial territories demonstrate excellent
intrareader and interreader agreement in patients imaged twice
with FDG PET with an interval of 2 weeks between studies
[40]. TBR is robust with different scan settings (acquisition
times and reconstruction filters) and tracer circulation times,
while SUV might show significant differences with each of
these settings [38, 41].
TBRmean and TBRmax have both been shown to be highly
reproducible [42]. However, reproducibility of a measurement
does not equal accuracy. On the one hand, TBR is calculated
as a ratio of two SUVs. TBR therefore compensates for errors
in patient weight, the dose of radiotracer injected and imaging
time-point. On the other hand, TBR varies as a function of
blood-pool activity (denominator). Blood-pool activity can be
affected by many factors including: (1) FDG uptake in circu-
lating blood cells, (2) chronic renal insufficiency, and (3)
blood glucose levels [38, 43]. In addition, measurement of
blood SUVmean can sometimes be challenging. Care should
therefore be taken to avoid any interference with high FDG
uptake in tissues adjacent to the right atrium (myocardium), to
the jugular vein (muscle, lymph node) and to the superior vena
cava (myocardium, aorta) when measuring blood SUVmean.
The SUVmean should be measured by drawing small ROIs in
venous structures (jugular veins, superior or inferior vena
cava) in different locations within the venous target vessel
and then averaged to approach one single most accurate value
for circulating blood-pool signal [38]. It has to be pointed out
that the FDG blood-pool activity should be measured in a
venous structure close to the target artery allowing data acqui-
sition in the same bed position of the PET scan. This ensures
that the delay between injection of tracer and data acquisition,
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and consequently tracer uptake in the arterial target structure
and the washout of tracer from the venous blood pool, will be
the same for the arterial and the venous vessel. Otherwise a
bias in the calculation of the TBR cannot be excluded.
The use of other structures or organs for measurement of
background activity, such as the liver, muscles, spleen and
adipose tissue, should be considered cautiously because of
the systemic character of atherosclerosis, which might lead
to altered FDG accumulation in these structures and, conse-
quently, to altered final results [38, 44–49].
It has been shown that arterial FDG uptake significantly
varies among arterial territories [40, 42]. In general, the mean
TBR of the carotid arteries is significantly higher than in all
aortic territories (ascending and descending aorta, aortic arch
and abdominal aorta) and the iliac and femoral arteries [40,
42]. In contrast, no significant difference has been observed
between the FDG uptake in the left and right carotid artery
[42]. These differences clearly have to be kept in mind, as
when comparing different scans intraindividually or
interindividually, the arterial FDG uptake needs to be com-
pared between the same arterial territories to avoid bias related
to the intrinsically different arterial FDG uptake patterns. This
holds true for both a "per-region/per-territory" aswell as a "per-
patient" analysis. Mainly for the latter, it is important not to
compare the highest FDG uptake identified in one patient scan
with the highest in another scan of the same or another patient
independent of the arterial territory (for example, carotid artery
versus aortic arch, etc.) because of the intrinsic differences in
FDG uptake between different arterial regions.
On basis of the TBR calculation, three different approaches
for the quantitative assessment of arterial FDG uptake in a
target (index) vessel have been developed and tested in clini-
cal trials [9, 13, 19, 30, 40, 42, 44, 47, 50]. The first approach
involves measuring the average TBR (TBRmean or TBRmax,
see below) along all the axial segments that comprise the
target vessel (whole vessel mean TBRmean or TBRmax;
Fig. 1) [9, 13, 30, 40, 42, 44, 50]. This approach might be
intrinsically more robust and less sensitive to image noise and
to FDG signal originating from structures adjacent to the ves-
sel wall as the signal will be averaged over a large number of
segments. On the other hand, this approach will be less sensi-
tive for detecting small changes over time in FDG uptake in
focal areas with atherosclerotic plaques [42, 51]. However, the
approach is well suited to the assessment of global vascular
inflammation in patients as a marker of cardiovascular risk
and for comparison with other surrogate markers of CVD
(Table 1).
The second approach involves measuring the average
TBRmax in a small segment of the index vessel with the
highest FDG uptake, the most diseased segment (MDS;
Fig. 1). In the study by Tawakol et al. [50], the MDS was
defined as a 1.5-cm arterial segment centred on the slice of
the target artery demonstrating the highest FDG uptake (as
quantified by TBRmax). The FDG uptake within the MDS
was then calculated as a mean of the TBRmax values from
three contiguous axial segments [50]. This approach was par-
ticularly well suited to evaluating the degree of inflammation
in a particular atherosclerotic plaque in an individual patient
(Table 1).
The third approach, active segment (AS) analysis, is based
on the methods used by Tahara et al. [19] and Elkhawad et al.
[47] and was applied by Emami et al. in a clinical trial (Fig. 1)
[52]. In this approach only arterial locations with a high
predefined FDG uptake at baseline are analysed. Only lesions
with increased FDG uptake (in the studies by Emami et al. and
Elkhawad et al. a TBR of ≥1.6) are then used to evaluate the
effect of therapeutic interventions on FDG uptake [19, 47, 52].
The optimal cut-off value indicating arterial segments, plaques
or arteries with actual inflammation is, however, still a matter
of debate, and needs to be defined. Previous FDG PET imag-
ing studies with pathological correlations demonstrate that a
TBR value <1.6 is associated with <5 % inflammation within
the atheroma [12, 53, 54]. However, it has yet to be proven
whether <5 % inflammation is not associated with an in-
creased cardiovascular risk. Irrespective of these consider-
ations, the AS approach, which focuses only on the plaques
with the most severe inflammation, might improve the sensi-
tivity of FDG PET imaging in identifying changes in FDG
uptake in atherosclerotic plaques in relation to the tested inter-
vention (Table 1).
Section summary and recommendations:
& For the quantification of FDG uptake in atherosclerotic
plaques, we recommend using TBR instead of SUV as
the use of a ratio between two measurements limits the
effects on signal quantification of errors in patient weight
and in the dose of radiotracer injected and of the imaging
time-point.
& When comparing arterial FDG uptake between different
scans the same arterial territory should be compared be-
cause of the intrinsically variable FDG uptake patterns in
different arterial regions, which may bias the results of, for
example, trials investigating the effect of interventions on
arterial FDG uptake.
& The choice of parameters used for quantification of FDG
uptake in the vascular wall depends on the aim of the
study: TBRmean and TBRmax are well suited to the assess-
ment of global vascular inflammation in patients as
markers of cardiovascular risk and to comparison with
other surrogate markers of CVD. The MDS is a relevant
approach when evaluating the degree of inflammation in
an individual atherosclerotic plaque in a patient. The ef-
fectiveness of therapeutic interventions on FDG uptake in
plaques might be improved by focusing on the arterial
segments with the highest FDG uptake at baseline using
metrics such as mean TBRmax, MDS and AS.
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Clinical relevance of FDG PET in atherosclerosis
Prognostic value of arterial FDG uptake
The prognostic value of FDG PET imaging of atherosclerosis
in predicting cardiovascular events was first tested retrospec-
tively in cohorts of patients who were undergoing FDG PET
imaging for oncological indications [41, 55–57]. Rominger
et al. found that in a large series of almost 1,000 patients
imagedwith FDGPET for cancer, the intensity of FDG uptake
in large arteries was a strong predictor of a subsequent vascu-
lar event [55]. Furthermore, patients with extensive calcifica-
tion of large arteries and high FDG uptake were at highest risk
of a cardiovascular event during follow-up [55]. Figueroa
et al. evaluated the incremental value of vascular PET imaging
for predicting cardiovascular events beyond the Framingham
risk score (FRS) [41]. In 514 individuals who fulfilled the
defined inclusion criteria of no prior CVD, absence of cancer
and ≥30 years of age, the intensity of FDG uptake was quan-
tified using TBR in the ascending aorta. Cardiovascular events
were defined as incident stroke, transient ischaemic attack,
acute coronary syndrome, revascularization, new-onset angi-
na, peripheral arterial disease, heart failure, or cardiovascular
related death. During a median follow-up period of 4.2 years,
44 participants had a cardiovascular event. The TBR not only
predicted the cardiovascular events independent of traditional
risk factors, but in addition to the FRS score improved the risk
evaluation in this population [41]. Marnane et al. prospective-
ly evaluated 60 patients with recent stroke, transient ischaemic
attack, or retinal embolism and ipsilateral carotid stenosis
(≥50 %) who had been imaged with FDG PET [56]. Patients
with the highest FDG uptake in the ipsilateral carotid plaques
were at the highest risk of an early recurrent stroke during
follow-up. The only independent predictor of stroke recur-
rence using a Cox regression model in this small group of
patients was high FDG uptake in carotid plaques [56].
FDG PETas surrogate endpoint in intervention studies
Effects of statin therapy on FDG uptake in arterial plaques
Tahara et al. imaged 43 cancer patients with FDG PET before
and after 3 months of low-dose statin (simvastatin 20 mg dai-
ly) or placebo treatment. This study was the first to show that a
significant decrease in the intensity of FDG uptake can be
detected as early as 3 months after the introduction of statin
therapy [19]. In two other studies the effect of statins on arte-
rial FDG uptake was investigated. In the first study a 7.9 %
reduction in aortic FDG TBR was observed after 6 months of
treatment with 20 mg per day of atorvastatin. In the second
study, a significant reduction in FDG signal following treat-
ment with atorvastatin wasmirrored by a decrease in the levels
of inflammatory biomarkers, including C-reactive protein
(CRP) measured using a high-sensitivity assay (hs-CRP)
[58–60]. Intensification of statin therapy with atorvastatin
from 10 mg to 80 mg per day led to a rapid reduction in
atherosclerotic inflammation as revealed by FDG PET 4 and
12 weeks after start with statin therapy [50]. Interestingly,
changes in TBR did not correlate with lipid profile changes,
indicating a lipid-independent antiinflammatory effect of
Fig. 1 Current most frequently
used approaches to quantifying
arterial FDG uptake in clinical
studies. All values given are
maximal target to background
ratios (TBRmax). ATBR threshold
of >1.6 was considered
significant for the active segment
analysis. The mean TBRmax of the
whole vessel would be 1.99, and
the mean TBRmax of the most
diseased segment would be 2.63
(based on a graph by Tawakol
et al. [64]). Image courtesy ©
Annette Bucerius
Eur J Nucl Med Mol Imaging (2016) 43:780–792 787
statins [50]. These clinical studies with statin therapy pave the
way for the use of FDG PET imaging for the evaluation of
new drugs aimed at reducing inflammatory activity in the
arterial wall and at plaque stabilization.
Evaluation of the effects of new antiatherosclerotic drugs
on arterial FDG uptake
The studies discussed above have increased the interest of the
pharmaceutical industry in FDG PET imaging for the evalua-
tion of new antiatherosclerotic drugs. The dal-PLAQUE study
is an interesting example of the potential role of plaque imag-
ing in the evaluation of new drugs [61, 62]. In this study,
participants were randomly assigned to receive the HDL
cholesterol-raising drug dalcetrapib or placebo. FDG PET
was performed at baseline and after 3 and 6 months treatment
to evaluate the effects of dalcetrapib on FDG uptake in aortic
and carotid atherosclerotic plaques. In addition, high-
resolution MRI of carotid plaques was performed at baseline,
and at 12 and 24months to test the effects of dalcetrapib on the
evolution of plaque volume. Baseline FDG PET was used to
select patients for study inclusion based on the magnitude of
FDG uptake in atherosclerotic plaques. Only patients with an
a priori-defined increased FDG uptake in plaques (TBR >1.6)
were included in the trial [61, 62]. Patients with the highest
reduction in FDG uptake after 6 months of treatment had the
highest increase in circulating HDL under treatment and pre-
sented with a subsequent reduction in plaque volume mea-
sured with MRI after 24 months of treatment [62]. This sug-
gests that a reduction in FDG uptake in atherosclerotic plaques
represents an early imagingmarker that precedes regression of
plaque volume and is associated with the efficacy of these
specific drugs.
Other similar therapeutic trials including substudies with
FDG PET imaging of plaques have been performed in recent
years. In one of these studies, the effect of a p38 mitogen-
activated protein kinase (p38MAPK) inhibitor, BMS-
582949, on atherosclerotic plaque inflammation in patients
with documented atherosclerosis was evaluated [52].
Patients were randomly assigned to treatment with BMS-
582949 (100 mg/day), atorvastatin (80 mg/day) or placebo.
Treatment with BMS-582949 for 12 weeks did not reduce
arterial inflammation or hs-CRP compared to placebo, where-
as intensification of statin therapy significantly decreased ar-
terial inflammation [52]. In another trial, the effects of VIA-
2291, a potent inhibitor of arachidonate 5-lipoxygenase, a key
enzyme in the synthesis of leukotrienes, on arterial inflamma-
tion was investigated in comparison with placebo [63]. VIA-
2291 has been shown to reduce hs-CRP and noncalcified cor-
onary plaque volume following an acute coronary syndrome.
Arterial inflammation was again quantified using FDG PET
and TBR. However, treatment with VIA-2291 was not asso-
ciated with a significant difference in inflammation compared
with placebo following 6 weeks and 24 weeks of treatment, or
with a significant reduction in hs-CRP from baseline [63].
Finally, the effects of rilapladib (an inhibitor of lipoprotein-
associated phospholipase A2, also known as platelet-
activating factor acetylhydrolase) on arterial inflammation
were investigated using FDG PET imaging in a multicentre,
randomized, placebo-controlled study [64]. No significant re-
ductions in FDGTBRwere observed in the index vessel in the
group treated with rilapladib [64]. Furthermore, lipoprotein-
associated phospholipase A2 inhibition by rilapladib also did
not enhance platelet aggregation [64, 65].
Section summary and recommendations:
& Measurement of FDG uptake in plaques is highly repro-
ducible between PET studies. This translates into the pos-
sibility of detecting significant changes in FDG uptake
with a relatively small group of patients.
& Initial FDG PET imaging can be used to screen patients
entering a clinical study and select only those with in-
creased FDG uptake in atherosclerotic plaques, who are
at the highest risk of a cardiovascular event and might
benefit the most from the tested drug.
& Changes in FDG uptake can be detected as early as
3 – 4 months after initiation of drug treatment, in contrast
to changes in plaque volume, which occur later
(12 – 24 months).
& Monitoring of the evolution of FDG uptake after initiation
of a new treatment can give a hint as to the beneficial or
deleterious effects of the drug on inflammatory activity in
atherosclerotic plaques, even though FDG uptake in
plaques is only a surrogate marker for the effects of drugs
on plaque stabilization.
& Recommendations regarding the arterial territories to
be analysed depending on the different study settings
are given in Table 1.
Perspectives in atherosclerotic plaque imaging
PET/MRI for imaging of atherosclerotic plaques
Most current clinical PETsystems are now combinedwith CT.
These systems allow successive CT and PET acquisitions. CT
acquisitions are used to generate tissue attenuation maps for
the correction of the PET acquisition. In addition, CT images
can be fused with the PET data to help localize areas accumu-
lating radiotracer. CT images allow localization of the princi-
pal organs in a patient, but may be insufficient to identify
precisely tissue structures in some clinical situations. These
limitations have stimulated the development of combined
PET/MRI systems. The main advantage of these systems is
to associate the high tissue contrast of MRI with PET imaging
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[66]. Combined PET/MRI systems may offer several advan-
tages for plaque imaging over PET/CT. First, imaging the
arteries and/or the arterial plaque with CT requires angiogra-
phy with injection of iodinated contrast agent, whereas with
MRI this detection can be performed without paramagnetic
contrast agents with dedicated sequences and "simply" using
the intrinsic contrast of moving protons (i.e. blood). Second,
as described previously, MRI allows arterial wall imaging
with high contrast and spatial resolution. Hence, PET/MRI
could offer the possibility to detect simultaneously both mor-
phological and biological characteristics of atherosclerotic
plaques. This will however require the implementation of
MR acquisitions protocols and surface coils dedicated to vas-
cular wall imaging in a combined PET/MRI system. Third, the
evaluation of radiotracer uptake in coronary atherosclerotic
plaques is difficult because of constant respiratory and cardiac
motion during PET acquisition. The development of prospec-
tive respiratory and cardiac gating with MRI during PET ac-
quisition could strongly improve the accuracy of PET mea-
surements in coronary arteries. In summary, promising clinical
applications are foreseen in the field of atherosclerotic plaque
imaging for combined PET/MRI acquisition but such applica-
tions require the development of dedicated innovative imag-
ing protocols in association with physicists [67].
New PET tracers for atherosclerosis imaging
An important limitation of FDG PET studies is, however, the
relatively nonspecific nature of FDG uptake. In particular,
myocardial and skeletal muscle FDG uptake is frequent and
often hampers precise analysis of coronary and carotid arter-
ies. In addition, imaging with FDG requires patients to fast for
at least 6 h before injection of the radiotracer to limit uptake by
peripheral muscle and is often associated with poor image
contrast in diabetic patients.
Therefore, new radiotracers more specifically targeting
high-risk plaques might be interesting alternatives to FDG
for the evaluation of atherosclerotic plaques with PET. In this
context, several radiotracers such as 11C-choline or 18F-cho-
line and 68Ga-DOTATATE, which bind to or accumulate in
inflammatory cells, have been evaluated in patients for the
detection of inflammation in atherosclerotic plaques [68–71].
The absence of any background signal in the myocardium
facilitates the detection of radiotracer uptake in coronary ar-
teries. For example, Rominger et al. were able to identify
68Ga-DOTATATE uptake in the left anterior descending artery
in 70 patients imaged for oncological indications [71]. More
recently, Folke Pederson et al. evaluated the intensity of 64Cu-
DOTATATE uptake with PET/MRI in ten atherosclerotic
plaques of patients scheduled for carotid endarterectomy
[72]. Significantly higher 64Cu-DOTATATE uptake was de-
tected in plaques ipsilateral to the ischaemic event than in the
contralateral carotid artery [72].
18F-sodium fluoride (NaF) is a positron-emitting bone-
seeking agent that reflects blood flow and remodelling of
bone. Therefore, NaF has attracted interest for the imaging
of calcified alterations in the arterial wall and in arterial
plaques. In a feasibility study, Derlin et al. retrospectively
evaluated imaging data obtained in 75 patients undergoing
whole-body NaF PET/CT [73]. NaF uptake was observed at
254 sites in 57 patients (76 %) and calcification was observed
at 1,930 sites in 63 patients (84 %) [73]. Colocalization of
radiotracer accumulation and calcification was observed in
223 areas of uptake (88 %). Interestingly, only 12 % of all
arterial calcification sites showed increased radiotracer up-
take, indicating that NaF might be much more sensitive in
detecting small calcified lesions, so-called spotty calcifica-
tions, and active calcium deposition than CT [73]. It is known
that both active and passive mechanisms of calcium deposi-
tion may explain arterial calcification and that plaque calcifi-
cation is an active process akin to bone formation [73].
Therefore, NaF uptake might be indicative of ongoing active
mineral deposition in atherosclerotic lesions. Such plaques
might not represent stable, non-progressive stages of disease
[73]. Irkle et al. have been able to confirm this assumption as
they showed a selective and specific high affinity of NaF for
calcified deposits within arterial plaques [74]. Most intrigu-
ingly, NaF was able to distinguish between areas of
macrocalcification and "active" microcalcification, the latter
indicative of nascent calcification and active unstable athero-
sclerosis [74].
The same group later investigated the correlation between
NaF accumulation in the common carotid arteries of neuro-
logically asymptomatic patients with cardiovascular risk fac-
tors and carotid calcified plaque burden [75]. They included
269 oncological patients who underwent NaF PET/CT. NaF
uptake in the common carotid arteries was observed at 141
sites in 94 patients (34.9 %) and showed colocalization with
calcification in all atherosclerotic lesions. NaF uptake was
significantly associated with age, male sex, hypertension and
hypercholesterolaemia [75]. The presence of calcified plaque
correlated significantly with these risk factors and also with
diabetes, history of smoking, and prior cardiovascular events.
Furthermore, there was also a highly significant correlation
between the NaF uptake and the number of cardiovascular
risk factors [75].
Joshi et al. reported the intriguing results of a prospective
clinical trial of arterial NaF PET imaging [76]. Two groups of
patients, 40 with myocardial infarction and 40 with stable
angina, underwent both NaF and FDG PET/CT as well as
invasive coronary angiography. NaF uptake was compared
with histology of carotid endarterectomy specimens from pa-
tients with symptomatic carotid disease, and with intravascu-
lar ultrasonography in patients with stable angina [76]. In 37
patients (93 %) with myocardial infarction, the highest coro-
nary NaF uptake was found in the culprit plaque. Interestingly,
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in contrast to the findings with NaF, which is not physiolog-
ically taken up by the myocardium, coronary FDG uptake was
commonly obscured bymyocardial uptake and where discern-
ible there were no differences between the culprit and
nonculprit plaques [76]. At the sites of all carotid plaque rup-
tures, significant NaF uptake was observed, which was asso-
ciated with histological evidence of active calcification, mac-
rophage infiltration, apoptosis and necrosis [76]. Plaques with
focal NaF uptake were seen in 18 (45 %) of the patients with
stable angina. Intravascular ultrasonography in these patients
revealed that plaques with increased NaF uptake had more
high-risk features, including positive remodelling,
microcalcification and a necrotic core, than those without
NaF uptake [76]. These promising results indicate that NaF
PET imaging might be a sensitive method for identifying and
localizing ruptured and high-risk coronary plaques.
Summary/statement
In the past 10 years, several studies have shown that FDG PET
imaging can reliably noninvasively evaluate the degree of
inflammation present in atherosclerotic plaques. Patients with
the highest FDG uptake in plaques show a higher rate of
cardiovascular events and a worse prognosis than patients
with low arterial FDG uptake. Hence, the FDG signal detected
in plaques seems relevant to the evaluation of patients with
atherosclerotic disease. One important limitation for the wider
use of FDG PET in plaque imaging is the large variety of
imaging protocols and quantification methods among centres.
The aim of this position paper was to review the different
parameters that can be chosen for atherosclerosis PET imaging
and, based on the existing literature and the expertise of differ-
ent European centres involved in plaque imaging, to define the
"optimal" imaging protocol for plaque imaging with PET.
Standardization of acquisition protocols for plaque imaging
with PET would facilitate comparison of publications in the
field and the setting up of meta-analyses and multicentre trials
including patients from several imaging centres in Europe. An
important challenge for the next years will be to evaluate
whether the information extracted from PET imaging could
play a role in the management of patients with atherosclerotic
plaques. For this purpose, clear threshold or diagnostic criteria
will need to be defined. Again, standardization of PET imaging
protocols will be critical to ensure the reproducibility and ro-
bustness of the chosen values among different imaging centres.
In the future, algorithms for, among other things, respira-
tory gating and resolution recovery, but mainly the use of
hybrid vascular PET/MRI, might provide a unique opportuni-
ty to combine morphological and functional evaluation of ath-
erosclerotic plaques. In addition, precise delineation of plaque
contours with high-resolution MRI might offer a more accu-
rate correction of PVE and improved quantification of
radiotracer accumulation in atherosclerotic plaques.
Furthermore, FDG has the advantage of wide availability but
has important limitations for plaque imaging including the
need for fasting, interaction with blood glucose levels, and
background signal in circulating blood and muscles.
Development of new PET radiotracers more specific as
markers of plaque vulnerability would greatly facilitate ath-
erosclerosis imaging and stimulate the implementation of this
technique.
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